A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

NCT06553339 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Oral HS-10516

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.